HK1081438A1 - Induction of antigen specific immune tolerance - Google Patents

Induction of antigen specific immune tolerance

Info

Publication number
HK1081438A1
HK1081438A1 HK06101602A HK06101602A HK1081438A1 HK 1081438 A1 HK1081438 A1 HK 1081438A1 HK 06101602 A HK06101602 A HK 06101602A HK 06101602 A HK06101602 A HK 06101602A HK 1081438 A1 HK1081438 A1 HK 1081438A1
Authority
HK
Hong Kong
Prior art keywords
induction
specific immune
antigen specific
immune tolerance
tolerance
Prior art date
Application number
HK06101602A
Other languages
English (en)
Inventor
Emil D Kakkis
Merry Passage
Thomas Lester
Rebecca Yang
Christopher Tanaka
Original Assignee
Biomarin Pharm Inc
Harbor Ucla Res & Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc, Harbor Ucla Res & Education filed Critical Biomarin Pharm Inc
Publication of HK1081438A1 publication Critical patent/HK1081438A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
HK06101602A 2002-05-06 2006-02-07 Induction of antigen specific immune tolerance HK1081438A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/141,668 US7485314B2 (en) 2002-05-06 2002-05-06 Induction of antigen specific immunologic tolerance
PCT/US2003/013843 WO2003094840A2 (en) 2002-05-06 2003-05-05 Induction of antigen specific immunologic tolerance

Publications (1)

Publication Number Publication Date
HK1081438A1 true HK1081438A1 (en) 2006-05-19

Family

ID=29399718

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101602A HK1081438A1 (en) 2002-05-06 2006-02-07 Induction of antigen specific immune tolerance

Country Status (16)

Country Link
US (3) US7485314B2 (ja)
EP (1) EP1507555B1 (ja)
JP (1) JP4933042B2 (ja)
CN (1) CN100360182C (ja)
AR (1) AR039882A1 (ja)
AU (1) AU2003228829B2 (ja)
BR (1) BR0309809A (ja)
CA (1) CA2492394A1 (ja)
ES (1) ES2401681T3 (ja)
HK (1) HK1081438A1 (ja)
IL (1) IL165016A (ja)
MX (1) MXPA04009292A (ja)
TW (1) TWI349556B (ja)
UY (1) UY27795A1 (ja)
WO (1) WO2003094840A2 (ja)
ZA (1) ZA200409787B (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
EP1848806A4 (en) * 2005-02-04 2009-09-09 Dow Agrosciences Llc ANTI-T CELL AND AUTOANTIGEN TREATMENT OF AN AUTOIMMUNE DISEASE
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
EP2132224B1 (en) * 2007-03-21 2011-12-28 Raptor Pharmaceutical Inc Cyclic receptor-associated protein (rap) peptides
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
ES2600932T3 (es) * 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
NZ609474A (en) * 2010-10-27 2015-06-26 Baxter Healthcare Sa Fviii peptides for immune tolerance induction and immunodiagnostics
CN107261154A (zh) 2011-04-29 2017-10-20 西莱克塔生物科技公司 致耐受性合成纳米载体
AU2012256281B2 (en) * 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
EP3453402B1 (en) 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
WO2013150284A1 (en) * 2012-04-02 2013-10-10 University Of Bristol Tolerisation- inducing composition
CN103372214B (zh) * 2012-04-13 2017-09-29 北京艾棣维欣生物技术有限公司 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
RU2680581C2 (ru) 2012-11-27 2019-02-22 Байомарин Фармасьютикал Инк. Направленные терапевтические химерные белки лизосомальных ферментов и их применение
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
CN115120745A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
EP3189138A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP3371593B1 (en) 2015-11-06 2020-10-14 BioMarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
KR20210024048A (ko) * 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법
JP2022513299A (ja) 2018-12-19 2022-02-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー リソソーム標的化のための二官能性分子ならびに関連する組成物および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
WO1992014485A1 (en) 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
ATE193208T1 (de) * 1992-02-10 2000-06-15 Univ Duke Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
JPH10513350A (ja) * 1995-01-31 1998-12-22 ザ ロックフェラー ユニヴァーシティ ＤＥＣ（樹状細胞及び上皮細胞、２０５ ｋＤａ）の同定、Ｃ型レクチンドメインを有するレセプター、ＤＥＣをコードする核酸、及びこれらの使用
CA2252790A1 (en) 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (sidr)
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20050191309A1 (en) * 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance

Also Published As

Publication number Publication date
WO2003094840A3 (en) 2004-03-11
EP1507555A4 (en) 2009-07-15
WO2003094840A2 (en) 2003-11-20
AU2003228829A1 (en) 2003-11-11
TWI349556B (en) 2011-10-01
JP4933042B2 (ja) 2012-05-16
CA2492394A1 (en) 2003-11-20
CN100360182C (zh) 2008-01-09
US20030211113A1 (en) 2003-11-13
US7485314B2 (en) 2009-02-03
ES2401681T3 (es) 2013-04-23
US20090238818A1 (en) 2009-09-24
EP1507555B1 (en) 2012-12-19
AR039882A1 (es) 2005-03-09
IL165016A (en) 2012-01-31
TW200400045A (en) 2004-01-01
ZA200409787B (en) 2006-07-26
JP2005530762A (ja) 2005-10-13
BR0309809A (pt) 2007-01-09
EP1507555A2 (en) 2005-02-23
IL165016A0 (en) 2005-12-18
UY27795A1 (es) 2003-11-28
CN1652814A (zh) 2005-08-10
US7883707B2 (en) 2011-02-08
AU2003228829B2 (en) 2009-05-21
MXPA04009292A (es) 2005-06-08
US20040009906A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
HK1081438A1 (en) Induction of antigen specific immune tolerance
EP1490101A4 (en) METHODS OF IMPROVING INDUCTION OF IMMUNE RESPONSE INVOLVING MDA-7
IL212419A0 (en) Methods of administering anti-tnf antibodies
EP1572131A4 (en) ANTIBODY THERAPY
HK1076223A1 (en) Induction heater
EP1437920A4 (en) INDUCTION HEATING DEVICE
GB2393760B (en) Induction system
HK1081792A1 (en) Induction heating coil
GB0214528D0 (en) Materials and methods for induction of immune tolerance
EP1509598A4 (en) INDUCTION OF INSULINE EXPRESSION
GB0320982D0 (en) Induction device
AU2003299823A8 (en) Methods of inducing and maintaining immune tolerance
GB0126378D0 (en) Antigen
EP1462456A4 (en) TUMOR ANTIGENS
IL156276A0 (en) Induction of tolerance
GB0220809D0 (en) Immune modulator
AU2002361682A8 (en) Innate immune system-directed vaccines
AU2003234190A8 (en) Inhibition of immune complex formation
EP1465699A4 (en) AUTOIMMUNE STIMULATION BY PHOTOPHORESIS
AU2003302234A8 (en) Immune response associated proteins
GB0215287D0 (en) 5T4 antigen expression
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
GB0504677D0 (en) Method of creating antigens using emus
EP1454914A4 (en) TUMOR ANTIGEN
AU2003228133A8 (en) Reduction of unwanted immune reactions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150505